US Rheumatologists’ Early Views on Eli Lilly’s Olumiant for the Treatment of Rheumatoid Arthritis Show Uphill Battle, While Pfizer’s Xeljanz Holds Ground as the Preferred JAK Inhibitor
The introduction of Olumiant after lengthy delays means Sanofi/Regeneron’s Kevzara is no longer the “new kid on the block” and has recently boasted significant growth. Download Report Overview EXTON, Pa., Aug. 20, 2018 /PRNewswire/ — Spherix Global Insights’ third quarter update of RealTime Dynamix™: Rheumatoid Arthritis (US) captured initial insights on Eli Lilly’s long-awaited launch […]
Branded Direct-to-Consumer Advertising Likely to Provide a Bump in Patient Requests for Sanofi/Regeneron’s Dupixent, but Insurance Coverage and Out-of-Pocket Costs Continue to be Key Barriers for the Only Approved Atopic Dermatitis Biologic
According to the latest update from Spherix Global Insights, while dermatologists continue to report high satisfaction with the first FDA approved biologic, there is still a large unmet need for new pharmacologic treatments for atopic dermatitis. Download Report Overview EXTON, Pa., August 15, 2018 /PRNewswire/ — Sanofi/Regeneron’s Dupixent continues to exceed expectations and current users […]
Spherix Global Insights Announces Real World Audit Abstracts Accepted for Presentation at the 34th Congress of ECTRIMS In Berlin, Germany
The two abstracts compare U.S. neurologists’ self-reported perceptions with actual prescribing behavior to assess if the use of highly effective therapies as first-line treatment is increasing over time and what disease metrics and treatment expectations drive the selection of monoclonal antibody agents in patients recently switched to a new therapy EXTON, Pa., Aug. 7, 2018 […]
Lupus Clinical Trials May Not Be Representative of Real-World Population, Report Suggests
From: Lupus News Today By: Iqra Mumal Patients participating in Phase 3 clinical trials testing new therapies for systemic lupus erythematosus (SLE) are not necessarily representative of real-world patient populations, according to a new report. Even if the therapies being investigated reach the market, real-world experiences may differ significantly from trial results […]
Pfizer’s Retacrit, the First Erythropoietin Stimulating Agent to be FDA Approved, Not Likely to See Rapid Adoption in the US Dialysis Market
Two-thirds of surveyed nephrologists do not expect their dialysis center to make Retacrit available for at least a year, if ever, according to the latest quarterly anemia report by Spherix Global Insights Download Report Overview EXTON, Pa., July 31, 2018 /PRNewswire/ — Plagued by regulatory delays, the FDA finally granted approval for Retacrit in May […]
Analysis of Over 1,000 Systemic Lupus Erythematosus Patients Reveals Real World Patient Populations are Not Representative of Clinical Trial Samples
While the systemic lupus erythematosus (SLE) pipeline has progressed with agents such as Janssen’s Stelara, AstraZeneca/MedImmune’s anifrolumab, Neovacs’ INF-K, and ImmuPharma’s Lupuzor, historically, most agents in development do not make it past phase III trials, resulting in an exceptionally high unmet need. Download Report Overview EXTON, Pa., July 25, 2018 /PRNewswire/ — To better understand […]
Amgen’s Parsabiv Doubles in Most Recent Quarter But Strict Usage Guidelines from Large Dialysis Organizations, DaVita and Fresenius Medical Care, Stifle Potential
The majority of nephrologists intend to increase their use of Parsabiv in the next quarter, but access at dialysis units proves to be the greatest barrier, according to a new report released by Spherix Global Insights Download Report Overview EXTON, Pa., July 24, 2018 /PRNewswire/ – Nephrologists largely believe that an IV calcimimetic (e.g. Parsabiv) […]
Recent Chart Audit of New Start Multiple Sclerosis Patients Confirms Dominance of the Oral Class, including Biogen’s Tecfidera, for First-Line Treatment But Finds Monoclonal Antibody Therapies, such as Genentech’s Ocrevus, Emerging as Legitimate Competitors
Teva’s Copaxone remains the brand share leader among new start patients year-over-year, although neurologists are beginning to write prescriptions for Mylan’s generic glatiramer acetate and Sandoz’s Glatopa independent of direct payer influence, according to a recently published independent audit from Spherix Global Insights Download Report Overview EXTON, Pa., July 23, 2018 /PRNewswire/ — The oral […]
Rheumatologist User Base for Eli Lilly’s Taltz in Psoriatic Arthritis (PsA) Boasts Strong Growth in Q2, While Use of Pfizer’s Xeljanz Has Remained Flat Over the Past Quarter
Download Report Overview EXTON, Pa., July 17, 2018 /PRNewswire/ — The most recent quarterly results of a study conducted by Spherix Global Insights with 100 US rheumatologists reveals that the user-base for Eli Lilly’s Taltz has more than doubled since the first quarter of 2018 while use of Pfizer’s Xeljanz has remained relatively flat after […]
Bolstered Skin Clearance Allows for Ample First-Line Use of Biologics with Alternate Mechanisms of Action for the Treatment of Psoriasis
Data from over 1,000 psoriasis patients initiated on biologic or small molecule therapy for the first time reveals agents with alternate mechanisms of action–Janssen’s Stelara and Tremfya, Novartis’ Cosentyx, Eli Lilly’s Taltz, and Celgene’s Otezla, account for more than two-thirds of all recent first-line psoriasis initiations. Download Report Overview EXTON, Pa., June 28, 2018 /PRNewswire/ […]
